TIDMPXS

RNS Number : 1765M

Provexis PLC

12 September 2019

12 September 2019

Provexis plc

("Provexis" or the "Company")

Director / PDMR notification

Provexis, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow(R) heart-health functional food ingredient, announces that Ian Ford, CEO and CFO, purchased a total of 5,000,000 ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") on 12 September 2019 at an average price of 0.338 pence per Ordinary Share.

Following this purchase, Mr Ford has a total beneficial interest in 10,000,000 Ordinary Shares, equivalent to 0.50% of the Company's issued share capital.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them are set out below pursuant to the EU Market Abuse regulation.

 
 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                        Ian Ford (Director and PDMR) - shares acquired 
                                   on behalf of Mr Ford's children (under the 
                                   age of 18) who are persons closely associated 
                                   with Mr Ford 
     --------------------------  ----------------------------------------------- 
 2    Reason for the notification 
     --------------------------------------------------------------------------- 
 a)   Position/status             See 1a) above 
     --------------------------  ----------------------------------------------- 
 b)   Initial notification        Initial notification 
       / Amendment 
     --------------------------  ----------------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     --------------------------------------------------------------------------- 
 a)   Name                        PROVEXIS PLC 
     --------------------------  ----------------------------------------------- 
 b)   LEI                         21380042E3Y3N9VZ6N48 
     --------------------------  ----------------------------------------------- 
 4    Details of the transaction(s): section to be repeated for (i) 
       each type of instrument; (ii) each type of transaction; (iii) 
       each date; and (iv) each place where transactions have been 
       conducted 
     --------------------------------------------------------------------------- 
 a)   Description of the          Ordinary Shares of 0.1p each 
       financial instrument, 
       type of instrument 
 
       Identification code         ISIN: GB00B0923P27 
     --------------------------  ----------------------------------------------- 
 b)   Nature of the transaction   Purchase of ordinary shares 
     --------------------------  ----------------------------------------------- 
 c)   Price(s) and volume(s)        Price(s)        Volume(s) 
                                     0.33 pence      2,500,000 
                                      and 
                                      0.345 pence     2,500,000 
                                                    ----------- 
     --------------------------  ----------------------------------------------- 
 d)   Aggregated information 
       - Aggregated volume 
       - Price                      5,000,000 shares 
 
                                    Average price of 0.338 pence per share 
     --------------------------  ----------------------------------------------- 
 e)   Date of the transaction     12 September 2019 
     --------------------------  ----------------------------------------------- 
 f)   Place of the transaction    London Stock Exchange, AIM Market 
     --------------------------  -----------------------------------------------

For further information please contact:

 
 Provexis plc                  Tel: 07490 391888 
  Dawson Buck, Chairman         enquiries@provexis.com 
  Ian Ford, CEO & CFO 
 Allenby Capital Limited       Tel: 020 3328 5656 
  Nick Naylor / Liz Kirchner

Notes for editors

About Provexis plc

AIM-listed Provexis is focused on the development, licensing and sales of its proprietary, scientifically-proven Fruitflow(R) heart-health functional food ingredient.

Provexis was founded in 1999 and is headquartered in Reading, Berkshire.

Provexis shares are traded on the AIM market of the London Stock Exchange under the ticker symbol PXS.

For further information, please visit www.provexis.com and www.fruitflowplus.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHGGUQGBUPBGCP

(END) Dow Jones Newswires

September 12, 2019 10:19 ET (14:19 GMT)

Provexis (LSE:PXS)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Provexis.
Provexis (LSE:PXS)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Provexis.